Find trials
Consejos para buscar

T Cell Response to COVID19 Vaccinated Individuals

Overview

Información sobre este estudio

The first aim of this study is to verify that the TCR beta sequencing and curation platforms we will be using are able to identify patients with severe COVID-19 based on the TCR repertoires. This may be accomplished by testing and analyzing results between two cohorts: patients presenting acutely to MCF with mild COVID-19 and patients presenting with severe COVID-19. This will be accomplished by utilizing the the immunoSEQ Human T-cell Receptor Beta (hsTCB) Assay (Adaptive Biothechnologies) and the publicly available ImmuneCODE Open Access Database to confirm previously published data (PMID: 34253751). Both procedures will be performed by the company that created both platforms, Adaptive Biothechnologies.

The second aim of this study is to sequence the TCR receptors of participating patients and identify TCR motifs that may indicate a predisposition to (or protection from) severe SARS-CoV-2, leading to possible risk stratification of such patients, and whether or not age, gender or ethnicity has any contribution to said risk. This may require that we examine all three cohorts listed in the Subject Information section.

The third aim is to measure SARS-CoV-2 anti-spike and anti-nucleocapsid antibodies to distinguish patients that have not been exposed to SARS-CoV-2 to those that have been exposed.

Elegibilidad para la participación

Los requisitos de elegibilidad de los participantes incluyen la edad, el sexo, el tipo y el estadio de la enfermedad, y los problemas de salud o tratamientos previos. Las pautas difieren de un estudio a otro e identifican quiénes pueden o no pueden participar. No hay garantía de que cada persona elegible que desee participar en un ensayo se inscribirá. Comunícate con el equipo del estudio para analizar la elegibilidad del estudio y la posible participación.

Inclusion Criteria:

  • All age groups and ethnicities will be included in this study, with a desired emphasis for older (> 55-years-old) and younger patients (< 35-years-old) and one-to-one ratio of male to female patients, including pediatric patients.
  • Patients with or without previous vaccination who are admitted to Mayo Clinic for COVID-19.
  • Vaccinated Mayo Clinic patients with asymptomatic or mild disease, which may include patients who present to the ED but then are discharged or dismissed.
  • Vaccinated Mayo Clinic patients and/or employees with no history of SARS-CoV-2 infection.

Exclusion Criteria:

  • Pregnant women.
  • Children less than 12 years of age.

Eligibility last updated 8/16/21. Questions regarding updates should be directed to the study team contact.

 

 

Sedes participantes de Mayo Clinic

Los estatus de los estudios cambian con frecuencia. Comunícate con el equipo del estudio para obtener la información más actualizada acerca de la posibilidad de participar.

Sede de Mayo Clinic Estatus Contacto

Rochester, Minn.

Investigador principal de Mayo Clinic

William Morice, M.D., Ph.D.

Comunícate con nosotros para obtener el estatus más reciente

Contact information:

Jenna Capelle

(507) 266-5017

Capelle.Jenna@mayo.edu

Jacksonville, Fla.

Investigador principal de Mayo Clinic

Aziza Nassar, M.D., M.P.H.

Abierto para la inscripción

Contact information:

Carla Palmucci CCRP

Palmucci.Carla@mayo.edu

More information

Publicaciones

Publications are currently not available

Otros temas en investigación

.
CLS-20528817

Mayo Clinic Footer